Ticker

Three IPOs and two SPACs priced this week, and two SPACs submitted filings. No IPOs are currently scheduled for the week ahead as the year's next mega IPO potentially comes into view. Street research is expected to for one company in the week ahead, and four lock-up periods will be expiring.

SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, Inc. (Iambic) (Nasdaq: IAM), a clinical-stage life sciences and technology company advancing novel medicines using its AI-driven platform, today announced the pricing of its initial public offering of 9,375,000 shares of common stock at a public offering price of $16.00 per share. All of the shares of common stock are being offered by Iambic. The gross proceeds from…

Iambic Therapeutics, which is backed by Nvidia , is aiming to raise as much as $159.4 million ​in its US IPO, a regulatory filing showed ‌on Thursday, as biotech companies remain a bright spot in an otherwise subdued IPO market.